Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that affects the prognosis of patients with liver disease and is considered an independent risk factor for hospitalization and death. Rifaximin has been approved for HE treatment. This review will analyze the effect of rifaximin on different...

Full description

Saved in:
Bibliographic Details
Published in:BMC gastroenterology 2024-03, Vol.24 (1), p.94-94, Article 94
Main Authors: Fang, Guihua, Liu, Shuna, Liu, Bin
Format: Article
Language:English
Subjects:
Ammonia
Bacteria
Brain diseases
Care and treatment
Cirrhosis
Clinical trials
Complications and side effects
Development and progression
Diagnosis
Disease prevention
Dosage and administration
Drug dosages
Drug resistance
Drug therapy
Evidence-based medicine
Health aspects
Hepatic encephalopathy
Hepatic Encephalopathy - drug therapy
Hepatic Encephalopathy - prevention & control
Humans
Inflammation
Intervention
Liver
Liver cirrhosis
Liver diseases
Liver transplants
Mental disorders
Meta-analysis
Methods
Mortality
Network Meta-Analysis
Patient compliance
Patient outcomes
Patients
Prognosis
Quality of life
Remission
Rifaximin
Rifaximin - therapeutic use
Risk Factors
Secondary Prevention
Side effects
Small intestine
Systematic review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that affects the prognosis of patients with liver disease and is considered an independent risk factor for hospitalization and death. Rifaximin has been approved for HE treatment. This review will analyze the effect of rifaximin on different stages of HE with differential application dosages and strategies by traditional and network meta-analyses. We performed a systematic search of PubMed, EmBase, and Cochrane Library databases up to February 26, 2023, to identify randomized controlled trials (RCTs) about rifaximin for the prevention and treatment of HE. The outcomes included incidence of HE and HE progression, HE reversal, mortality, and adverse effects. A total of 21 studies were included. In the primary prevention of HE, rifaximin significantly reduced the incidence of HE (OR: 0.66; 95% CI: 0.45, 0.96; p = 0.032). In secondary prevention, rifaximin significantly reduced the risk of recurrence in patients who were in remission (OR: 0.38; 95% CI: 0.28, 0.52; p 
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-024-03184-0